US · CELU · BIOTECHNOLOGY
Celularity Inc. (CELU) intrinsic value and stock valuation
$0.46as of 2026-11-21 · Mkt cap 21.25M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Celularity Inc. DCF and intrinsic value
InvestorsCraft values CELU with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CELU’s statements →
Celularity Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18M | $21.3M |
| Operating income | -$-61.31M | -$-38.36M | -$-192.29M | -$-25.6M | -$-109.06M |
| Net income | -$-91.8M | -$-57.89M | -$-196.29M | $14.2M | -$-100.12M |
| EPSd | -$-3.59M | -$-2.64M | -$-11.02M | $947.3K | -$-7.86M |
| Operating cash flow | -$-13.25M | -$-6.4M | -$-38.69M | -$-137.88M | -$-110.1M |
| Capital expenditure | $0.00 | -$-160K | -$-4.05M | -$-5.24M | -$-6.2M |
| Free cash flow | -$-13.25M | -$-6.56M | -$-42.73M | -$-143.11M | -$-116.3M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Total debt | $40.9M | $68.8M | $65.4M | $65.6M | $31.1M |
| Net debt | $34.7M | $68.1M | $65.2M | $51.6M | -$-6.1M |
| Total equity | -$-38.06M | $8.84M | $41M | $198.9M | $99.4M |
| Cash and short-term investments | $6.17M | $740K | $230K | $14M | $37.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $26.6M | $54.2M | $22.8M | $18M | $21.3M |
| Cost of revenue | $6.36M | $15M | $16M | $19.7M | $9.65M |
| Gross profit | $20.2M | $39.2M | $6.75M | -$-1.69M | $11.7M |
| Research and development expenses | $15M | $17.4M | $30.5M | $78.4M | $88.4M |
| Selling, general and administrative expenses | $51.3M | $58.6M | $50.6M | $66M | $71.3M |
| Other expenses | $15.2M | $1.56M | $118M | -$-120.47M | -$-38.95M |
| Operating expenses | $81.5M | $77.6M | $199M | $23.9M | $120.7M |
| Cost and expenses | $87.9M | $92.6M | $215.1M | $43.6M | $130.4M |
| Interest income | $260K | $330K | $320K | $360K | $330K |
| Interest expense | $6.75M | $6.26M | $3.02M | $0.00 | $3.17M |
| Depreciation and amortization | $7.29M | $7.92M | $9.32M | $9.44M | $8.82M |
| Ebitda | -$-77.66M | -$-43.71M | -$-183.95M | -$-138.83M | -$-88.11M |
| Operating income | -$-61.31M | -$-38.36M | -$-192.29M | -$-25.6M | -$-109.06M |
| Total other income/expenses, net | -$-30.41M | -$-19.53M | -$-4M | $39.8M | $8.96M |
| Income before tax | -$-91.71M | -$-57.89M | -$-196.28M | $14.2M | -$-100.1M |
| Income tax expense | $0.00 | $0.00 | $10K | $10K | $20K |
| Net income | -$-91.8M | -$-57.89M | -$-196.29M | $14.2M | -$-100.12M |
| Weighted average shares outstanding | $25.6M | $21.9M | $17.8M | $14M | $12.7M |
| Weighted average diluted shares outstanding | $25.6M | $21.9M | $17.8M | $15M | $12.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $6.17M | $740K | $230K | $14M | $37.2M |
| Net receivables | $4.65M | $13.6M | $12.1M | $6.97M | $5.23M |
| Inventory | $570K | $5.41M | $5.75M | $5.31M | $9.55M |
| Total current assets | $12.3M | $20.6M | $19.8M | $33.5M | $59.1M |
| Property, plant and equipment, net | $66.5M | $72.4M | $78.8M | $88.7M | $90.6M |
| Goodwill and intangible assets | $15.1M | $16.6M | $18.4M | $240.7M | $246.5M |
| Long-term investments | $0.00 | $10.2M | $9.94M | $14.8M | $14.8M |
| Total non-current assets | $95M | $112.1M | $124.1M | $367.6M | $355M |
| Total assets | $107.3M | $132.7M | $143.9M | $401.1M | $414.1M |
| Accounts payable | $26.4M | $23.3M | $14.1M | $5.81M | $9.32M |
| Short-term debt | $14M | $6.36M | $39.2M | $37.6M | $3.05M |
| Deferred revenue | $5.25M | $3.53M | $2.83M | $2.27M | $2.2M |
| Total current liabilities | $80.8M | $53.7M | $67.3M | $62.1M | $26.2M |
| Long-term debt | $26.9M | $62.5M | $26.2M | $28M | $28.1M |
| Deferred revenue, non-current | $2.8M | $2.72M | $3.19M | $2.22M | $1.87M |
| Total non-current liabilities | $64.6M | $70.2M | $35.6M | $140.1M | $288.5M |
| Capital lease obligations | $26.9M | $26.6M | $26.2M | $28M | $28.1M |
| Total liabilities | $145.4M | $123.8M | $102.9M | $202.2M | $314.7M |
| Common stock | $0.00 | $0.00 | $20K | $10K | $10K |
| Retained earnings | -$-991.48M | -$-899.68M | -$-841.79M | -$-645.5M | -$-663.68M |
| Accumulated other comprehensive income (loss) | $0.00 | -$-10K | $0.00 | $10K | $0.00 |
| Total equity | -$-38.06M | $8.84M | $41M | $198.9M | $99.4M |
| Total investments | $0.00 | $10.2M | $9.94M | $14.8M | $14.8M |
| Total debt | $40.9M | $68.8M | $65.4M | $65.6M | $31.1M |
| Net debt | $34.7M | $68.1M | $65.2M | $51.6M | -$-6.1M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-91.72M | -$-57.89M | -$-196.29M | $14.2M | -$-100.12M |
| Depreciation and amortization | $7.29M | $7.92M | $11.5M | $9.44M | $8.82M |
| Stock-based compensation | $10.4M | $11.6M | $15M | $15.9M | $40M |
| Change in working capital | $33.6M | $22.2M | -$-6.77M | -$-15.45M | -$-5.71M |
| Accounts receivable | $7.55M | -$-3.97M | -$-6.83M | -$-3.58M | -$-1.91M |
| Inventory | $10.3M | $6.28M | -$-860K | -$-16.89M | -$-6.42M |
| Accounts payable | $3.13M | $9.24M | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-13.25M | -$-6.4M | -$-38.69M | -$-137.88M | -$-110.1M |
| Investments in property, plant and equipment | $0.00 | -$-160K | -$-4.05M | -$-5.24M | -$-6.2M |
| Acquisitions, net | $0.00 | -$-1.5M | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | $0.00 | $510K | -$-4.05M | -$-5.24M | -$-5.9M |
| Common stock issued | $24.4M | $60K | $5.43M | $53.4M | $640K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-5.9M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $18.7M | $6.7M | $24.1M | $119.8M | $98.6M |
| Net change in cash | $5.39M | $810K | -$-18.64M | -$-23.27M | -$-17.44M |
| Cash at end of period | $16.4M | $11M | $10.2M | $28.8M | $52.1M |
| Operating cash flow | -$-13.25M | -$-6.4M | -$-38.69M | -$-137.88M | -$-110.1M |
| Capital expenditure | $0.00 | -$-160K | -$-4.05M | -$-5.24M | -$-6.2M |
| Free cash flow | -$-13.25M | -$-6.56M | -$-42.73M | -$-143.11M | -$-116.3M |
Line items
Line items
Line items
About Celularity Inc.
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
- CEO
- Robert Joseph Hariri
- Employees
- 115
- Beta
- 0.54
Explore
Frequently asked questions
What is the intrinsic value of Celularity Inc. (CELU)?
InvestorsCraft does not currently publish an intrinsic value for CELU. How the IC value is calculated.
Is CELU undervalued?
InvestorsCraft does not publish an undervaluation signal for CELU at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.